T cells work together to fight cancer.
Recent studies have identified new melanoma antigens that are recognised by CD4(+) T cells. Analysis of tumour-specific CD4(+) T-cell responses may lead to the development of optimal anti-cancer vaccines that can induce an orchestrated effort of tumour-specific CD4(+) and CD8(+) T cells in the fight against cancer.
Cerundolo
V
V
Institute of Molecular Medicine Nuffield Department of Medicine Oxford, OX3 9DS, UK. vcerundo@worf.molbiol.ox.ac.uk
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007157:Immunologic Surveillance; D008545:Melanoma / Q000276:immunology; D051379:Mice; D018448:Models, Immunological; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D009374:Neoplasms, Experimental / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000949:Histocompatibility Antigens Class II